Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase I Safety, Pharmacokinetic & Dosimetry Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma

NCT00399113 is registered in ClinicalTrials.gov with Pain Therapeutics as lead sponsor.

NCT NCT00399113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00399113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase I Safety, Pharmacokinetic & Dosimetry Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
Lead sponsor
Pain Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2007
Completion date
Not reported
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma